drugset / Trial / NCT02406950
Sitagliptin and Endothelial Dysfunction
RandomizedCrossoverSingle-blindPrevention
Summary
Over the years, numbers of cardioprotective drugs have been evaluated to attenuate lethal ischemia-reperfusion (IR) injuries. There is little study whether sitagliptin protects against endothelial dysfunction induced by IR injury in humans.
Timeline
- Start
- 2015-02
- Primary completion
- 2015-06
- Completion
- 2015-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sitagliptin | Small molecule | 50 mg | — |
Indications
No indication recorded.